Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Iscience|March 23, 2019
Werner Syndrome Helicase Is Required for the Survival of Cancer Cells with Microsatellite InstabilityLorn Kategaya, Senthil K Perumal, Jeffrey H Hager, et al.
Molecular Cancer Therapeutics|February 4, 2012
Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer modelsMaureen Wong, Nguyen Tan, Jiping Zha, et al.
Cancer Research|July 22, 2010
A chemosensitization screen identifies TP53RK, a kinase that restrains apoptosis after mitotic stressDavid Peterson, James Lee, Xingye C Lei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer modelsNguyen Tan, Mehnaz Malek, Jiping Zha, et al.
The Biochemical Journal|November 26, 2014
Ubiquitination profiling identifies sensitivity factors for IAP antagonist treatmentEugene Varfolomeev, Anita Izrael-Tomasevic, Kebing Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2012
GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivoJeffrey J Wallin, Jane Guan, Wei Wei Prior, et al.
Molecular Cancer Therapeutics|March 12, 2013
Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor modelsNguyen Tan, Maureen Wong, Michelle A Nannini, et al.
Neoplasia (New York, N.Y.)|November 9, 2013
Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618Yang Xiao, Kristi Elkins, Jenni K Durieux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitorsDavid S Shames, Kristi Elkins, Kimberly Walter, et al.
Plos One|October 7, 2014
Structural basis for resistance to diverse classes of NAMPT inhibitorsWeiru Wang, Kristi Elkins, Angela Oh, et al.
Pageof 2